CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$3.14
-0.02 (-0.63%)
âŧ
5d:
-3.68%
30d:
-0.95%
90d:
+14.18%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 9, 2026 at $3.16 · last confirmed Sep 9, 2026
Strength: 7.4/10
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -1.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -1.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $3.14, which is considered fair relative to its 30-day fair value range of $2.98 to $3.40. The stock's valuation (Forward PE: 19.8) is in line with its historical norms (21.0). Remarkably, the market is currently pricing in an annual earnings decline of 1.9% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $3.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRON scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.54. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $3.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRON scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.54. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.98 -
$3.40
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
40.5%
Protect Your Profits
Holding CRON? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 19.3% above Wall St target ($2.54)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.98 -
$3.40
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.11
Resistance Level
$3.42
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.84
Wall Street Target
$2.54
(-19.3%)
Revenue Growth (YoY)
58.4%
Earnings Growth (YoY)
126.8%
Profit Margin
39.1%
Valuation Discount vs History
-1.9% cheaper
PE vs Historical
19.8 vs 21.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.9%
(market-implied from PE analysis)
1-Year Target
$3.08
(-2%)
2-Year Target
$3.02
(-4%)
3-Year Target
$2.96
(-6%)
3-Yr Target (if PE normalizes)
(PE: 20â21)
$3.14
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: -28.3%)
$2.33
(+-26%)
Base:
(SPY PE: 19.8, Growth: -28.3%)
$2.29
(-27%)
Bear:
(PE: 16.9, Growth: -28.3%)
$1.95
(-38%)
đ
Valuation based on Current Earnings
Trailing PE: 16.63 | Current EPS (TTM): $0.19
Bull Case
$2.90
(-8%)
Analyst growth -16.7%, PE expands to 18.3
Base Case
$2.63
(-16%)
Market implied -16.7%, PE stable at 16.6
Bear Case
$2.15
(-32%)
Severe decline -20.0%, PE contracts to 14.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.8 to 21.0
Stabilization Target:
$3.32
(+5.9%)
PE Expansion Potential:
+5.9%
Share & Embed Analysis
Last updated: September 13, 2026 3:34 PM ET
Data refreshes hourly during market hours. Next update: 4:34 PM
Data refreshes hourly during market hours. Next update: 4:34 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
